There are some variables we did not assess, which might nevertheless be moderators of psychosocial burden in TP53 VC, namely the percentage of de novo participants, whether participants were currently undergoing cancer treatment, current psychosocial support, and critical life events (Peters et al., 2016). The gene discussed is TP53; the disease is cancer.